DCTY1102

**DCTY1102** is an investigational TCR-T cell therapy designed for patients with advanced solid tumors that harbor the KRAS G12D mutation and express the HLA-A*11:01 genotype. The therapy involves the infusion of autologous T cells genetically engineered to express a T-cell receptor (TCR) specific for KRAS G12D. This approach enables targeted recognition and elimination of tumor cells expressing this mutation, representing a precision immunotherapy modality. DCTY1102 is being developed by Beijing Dingcheng Peptide Source Biotech Co., Ltd. and is in Phase 1 clinical trials with primary target indications including colorectal cancer, pancreatic cancer, and other advanced solid tumors[1][3][7][5][9].

Brand names

DCTY1102DCTY-1102DCTY 1102

Other names

DCTY1102DCTY-1102DCTY 1102